Aytu BioPharma announces patent term extension for EXXUA

Aytu BioPharma (AYTU) announced that the method of use patent for EXXUA extended-release tablets has been extended through September 2, 2030 under 35 U.S.C. 156. The patent extension further expands upon the new chemical entity exclusivity period granted by the United States Food and Drug Administration. Gepirone is an NCE, and EXXUA is the first-in-class selective serotonin 5HT1a receptor agonist approved by the FDA for the treatment of major depressive disorder in adults.